 Home > Pharmaceutical Intermediates > Antineoplastics > Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl] for Sale > Tepotinib API - A Potent MET Inhibitor for Non-Small Cell Lung Cancer.

Tepotinib API - A Potent MET Inhibitor for Non-Small Cell Lung Cancer. buy - large image1

Tepotinib API - A Potent MET Inhibitor for Non-Small Cell Lung Cancer. buy - image1

Tepotinib API - A Potent MET Inhibitor for Non-Small Cell Lung Cancer. buy - image2

Tepotinib API - A Potent MET Inhibitor for Non-Small Cell Lung Cancer.

Name: Tepotinib API - A Potent MET Inhibitor for Non-Small Cell Lung Cancer.
Brand: Tianrui
SKU: pr2511131384
Price: 11 USD
Availability: InStock

Unit Price: Get Latest Price 

CAS No.:

1100598-32-0

Grade:

Pharmaceutical Grade

Content:

98.5%

Port:

Qingdao

Brand:

Tianrui

Packaging:

Sealed fiber drum

Price valid (until):

2025-11-12

Contact Supplier

 Chat Now

Hefei Tianrui Pharmaceutical Chemical Co., Ltd.

Company Type:

Manufactory

Location:

China

Payment Terms:

TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average Lead Time:

15 days

Qualification:

Main Products:

APIs

 Visit Store

Product Description
Seller Information

Description

About Product

Tepotinib (CAS: 1100598-32-0) is a high-purity, chiral active pharmaceutical ingredient (API) that functions as a highly selective MET tyrosine kinase inhibitor. It is specifically developed for the treatment of non-small cell lung cancer with MET exon 14 skipping mutations, representing a breakthrough in precision medicine. Manufactured by Hefei TianRui Pharmaceutical under strict cGMP conditions, our Tepotinib API guarantees high chiral purity, controlled impurities, and reliable quality for targeted cancer therapies.

Items	Specifications
Product Name	Tepotinib
CAS Registry Number	1100598-32-0
IUPAC Name	N-[5-[(3R)-3-(1,3-benzodioxol-5-ylmethylamino)-1-piperidyl]-2-(2,6-difluorophenyl)pyridin-3-yl]cyclopropanecarboxamide
Molecular Weight	600.66 g/mol
Solubility	It is soluble in DMSO, soluble in methanol, and slightly soluble in water.
Melting Point	280-283°C
Primary Use	Non-small cell lung cancer with MET exon 14 skipping mutation Advanced or metastatic NSCLC

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 1

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 2

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 3

Company Profile

Founded: 2014
Focus: High-tech enterprise specializing in the development and industrialization of small-molecule pharmaceutical synthesis technology
Facilities:
- Two workshops (TR1 & TR2) with total capacity ≈ 1000 tons/year
- Reactors: 3000L×15, 2000L×10, and numerous smaller reactors (1000L, 500L, 100L)
- Ultra-low temperature cryogenic reactor (explosion-proof workshop included)
- GMP workshop & clean room
QC Lab Equipment: GC×2, HPLC×3, UV, IR, KF titrator, etc.

About company

Shop Roflumilast API - A Selective PDE4 Inhibitor for COPD Maintenance Treatment.-Detailed Image 7

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.

ECHEMI Editorial Reference

EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. IC50 Value: 4 nM [1]Target: c-Metin vitro: EMD 1214063 inhibits HGF-induced c-Met phosphorylation in A549 cells with IC50 of 6 nM. Treatment with EMD 1214063 induces a marked reduction of c-Met–constitutive phosphorylation in EBC-1 cells with IC50 of 9 nM. EMD 1214063 effectively blocka phosphorylation of the major downstream effectors of the c-Met
Tepotinib is under investigation in clinical trial NCT03531762 (Effect of a Proton Pump Inhibitor on the Pharmacokinetics (PK) of Tepotinib).|Tepotinib is a Kinase Inhibitor. The mechanism of action of tepotinib is as a Mesenchymal Epithelial Transition Inhibitor, and P-Glycoprotein Inhibitor.|Tepotinib is an orally bioavailable inhibitor of MET tyrosine kinase with potential antineoplastic activity. Tepotinib selectively binds to MET tyrosine kinase and disrupts MET signal transduction pathways, which may induce apoptosis in tumor cells overexpressing this kinase. The receptor tyrosine kinase MET (also known as hepatocyte growth factor receptor or HGFR), is the product of the proto-oncogene c-Met and is overexpressed or mutated in many tumor cell types; this protein plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.

Basic Info

Product Name:

Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]

Other Name:

Veledimex;3-(1-(3-(5-((1-Methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-;Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl];3-(1-(3-(5-((1-Methylpiperidin-4-yl)Methoxy)pyriMidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile;EMD-1214063;3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile;Tepotinib;Tepotinib (EMD 1214063)

CAS No.:

1100598-32-0

Molecular Formula:

C29H28N6O2

InChIKeys:

AHYMHWXQRWRBKT-UHFFFAOYSA-N

Molecular Weight:

492.57162

Exact Mass:

492.227386

UNII:

1IJV77EI07

DSSTox ID:

DTXSID70149132

NCI Thesaurus Code:

C88314

ATC Code:

L - Antineoplastic and immunomodulating agents

Categories:

Antineoplastics

Characteristics

PSA:

94.7

XLogP3:

3.4

Density:

1.25

Boiling Point:

626.5±65.0 °C(Predicted)

Flash Point:

332.7±34.3 °C

Refractive Index:

1.660

See More Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl] Properties 

Hazard Identification

Classification of the substance or mixture

no data available

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)	no data available
Signal word	no data available
Hazard statement(s)	no data available
Prevention	no data available
Response	no data available
Storage	no data available
Disposal	no data available

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl] Safety Data Sheet 

Seller Information

Business Type:
Manufactory

Main Products:
APIs

Location:
No.23,lntersection of Fenglehe Avenue and Leiyang Road, Huagang Town,Feixi County, Hefei, Anhui, China.

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
15 days

Total Annual Revenue:
$50 million-$100 million

Total Employees:
11-50

Year of Establishment:
2014

About TianRui

Hefei TianRui Pharmaceutical Chemical Co., Ltd was founded in 2014 as a high-tech enterprise focused on the development and industrialization of pharmaceutical small molecule synthesis technology. Our workshop and R&D center are located in Hefei HuaGang Provincial Industrial Park, Anhui Province. We are committed to providing professional technical services and commercialization of small molecule specialty APIs, CGMP standard intermediates, and functional pharmaceutical excipients and MRNA vaccine vectors for domestic and overseas well-known pharmaceutical companies.

Main Events

In 2015, the company developed polypeptide absorbent permeation enhancers: ethyl 8-bromo-octanoate and Carsalam, which is the 1st and only qualified Chinese supplier of Semaglutide to meet the internal control requirements of innovator Novo Nordisk.

In 2020, the company independently developed and optimized 8-bromo-octanoic acid and 6-bromo-caproic acid to become a COVID-19 vaccine carrier manufacturer and supplier to Moderna company, contributing its share to the fight against COVID-19.

In 2022, Tianrui R&D Center and cGMP manufacturing facility was inaugurated and put into operation. And in the same year, polypeptide absorbent permeation enhancers SNAC (Salcaprozate Sodium) has successfully obtained the domestic CDE registration number (F20220000072) and the US FDA registration number (037135), and another batch of innovative APIs and pharmaceutical excipients are under registration and approval.
Country Product Purchase Quantity Date Posted

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
EMD 1214063	/99.00		HANGZHOU LEAP CHEM CO., LTD.	Inquiry

Tepotinib API - A Potent MET Inhibitor for Non-Small Cell Lung Cancer.

Product Description

Seller Information